loading

Biodexa Pharmaceuticals Plc Adr Aktie (BDRX) Neueste Nachrichten

pulisher
Jul 28, 2025

Biodexa advances FAP treatment with phase 3 trial initiation By Investing.com - Investing.com South Africa

Jul 28, 2025
pulisher
Jul 28, 2025

Breakthrough FAP Treatment Enters Phase 3: How Biodexa Could Transform $7B Cancer Prevention Market - Stock Titan

Jul 28, 2025
pulisher
Jul 16, 2025

Biodexa Pharmaceuticals Announces ADR Ratio Change Effective July 31, 2025 - The Globe and Mail

Jul 16, 2025
pulisher
Jul 15, 2025

Biodexa Pharmaceuticals Announces Reverse ADR Split to Regain Nasdaq Compliance - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

Biodexa Pharmaceuticals PLC Announces ADR Ratio Change Effective July 31, 2025 - Nasdaq

Jul 15, 2025
pulisher
Jul 15, 2025

Biodexa Pharmaceuticals to implement 1:10 ADR ratio change - Investing.com

Jul 15, 2025
pulisher
Jul 15, 2025

Biodexa Pharmaceuticals PLC Announces ADR Ratio Change from 1:10 to 1:100,000. - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

MFS Extends Deadline for Liquidity Event for MFS Investment Grade Municipal Trust - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

ADR Ratio Change - GlobeNewswire

Jul 15, 2025
pulisher
Jul 15, 2025

Biodexa Plans Major ADR Restructuring: 1:10 Reverse Split to Meet Nasdaq Requirements - Stock Titan

Jul 15, 2025
pulisher
Jul 14, 2025

Biodexa files European clinical trial application for FAP treatment By Investing.com - Investing.com India

Jul 14, 2025
pulisher
Jul 14, 2025

Biodexa files European clinical trial application for FAP treatment - Investing.com

Jul 14, 2025
pulisher
Jul 14, 2025

Biodexa's $20M-Backed Phase 3 Trial for Rare Cancer Prevention Drug Expands to Europe - Stock Titan

Jul 14, 2025
pulisher
Jul 14, 2025

SMX (Security Matters) Plc (SMX) Stock: Navigating Drops and Gains - investchronicle.com

Jul 14, 2025
pulisher
Jul 14, 2025

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) - GlobeNewswire

Jul 14, 2025
pulisher
Jul 09, 2025

Company’s Banking Stock: Dissecting a 60.04% Quarterly Revenue Decline Amid Growth - investchronicle.com

Jul 09, 2025
pulisher
Jun 27, 2025

Biodexa Pharmaceuticals Secures 100% Shareholder Approval for Key Corporate Decisions at AGM - Stock Titan

Jun 27, 2025
pulisher
Jun 25, 2025

Biodexa Announces Activation of First Clinical Study Site - GlobeNewswire

Jun 25, 2025
pulisher
Jun 23, 2025

Biodexa Unveils Phase 3 FAP Trial "Serenta": New Hope for Rare Disease Patients - Stock Titan

Jun 23, 2025
pulisher
Jun 18, 2025

Biodexa enrolls first patient in type 1 diabetes drug trial - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Breakthrough Oral Diabetes Drug Enters Phase 2 Trial, Could Replace Daily Insulin Injections for Millions - Stock Titan

Jun 18, 2025
pulisher
Jun 13, 2025

Biodexa Pharmaceuticals changes share nominal value By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Biodexa Pharmaceuticals changes share nominal value - Investing.com

Jun 13, 2025
pulisher
Jun 11, 2025

Biodexa shareholders approve all resolutions at general meeting By Investing.com - Investing.com India

Jun 11, 2025
pulisher
Jun 11, 2025

Biodexa shareholders approve all resolutions at general meeting - Investing.com

Jun 11, 2025
pulisher
Jun 04, 2025

Phase 2 Trial Begins: Biodexa's Breakthrough Type 1 Diabetes Drug Shows Promise in Human Cells - Stock Titan

Jun 04, 2025
pulisher
May 22, 2025

Biodexa secures additional $3M for cancer drug trial By Investing.com - Investing.com India

May 22, 2025
pulisher
May 22, 2025

BDRXBiodexa Pharmaceuticals plc Latest Stock News & Market Updates - Stock Titan

May 22, 2025
pulisher
May 22, 2025

Biodexa secures additional $3M for cancer drug trial - Investing.com

May 22, 2025
pulisher
May 20, 2025

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here - sharewise

May 20, 2025
pulisher
May 20, 2025

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Nasdaq

May 20, 2025
pulisher
May 15, 2025

Biodexa Pharmaceuticals adjusts warrant exercise price - Investing.com

May 15, 2025
pulisher
May 15, 2025

Biodexa Pharmaceuticals adjusts warrant exercise price By Investing.com - Investing.com India

May 15, 2025
pulisher
May 12, 2025

Biodexa gains orphan drug status in EU for colon disease treatment - Investing.com

May 12, 2025
pulisher
May 12, 2025

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP - GlobeNewswire

May 12, 2025
pulisher
May 02, 2025

Biodexa Special Resolution Falls 4% Short: Chairman Promises New Fundraising Proposals - Stock Titan

May 02, 2025
pulisher
Apr 24, 2025

What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock - MSN

Apr 24, 2025
pulisher
Apr 17, 2025

Biodexa Shareholders to Vote on Strategic Share Subdivision Plan: Key Meeting Details Revealed - Stock Titan

Apr 17, 2025
pulisher
Apr 11, 2025

Preliminary Results for the Year Ended 31 December 2024 - GlobeNewswire

Apr 11, 2025
pulisher
Mar 19, 2025

Biodexa Pharmaceuticals advances FAP treatment trial By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Biodexa Pharmaceuticals advances FAP treatment trial - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter - BioSpace

Mar 19, 2025
pulisher
Mar 10, 2025

Biodexa gets FDA nod for Phase 3 eRapa study in FAP - Investing.com India

Mar 10, 2025
pulisher
Mar 10, 2025

FDA Clears Biodexa's Phase 3 Protocol for Rare Disease Drug eRapa - Stock Titan

Mar 10, 2025
pulisher
Mar 07, 2025

Why Plus Therapeutics, Inc. (PSTV) Soared on Thursday - Yahoo Finance

Mar 07, 2025
pulisher
Mar 06, 2025

Biodexa selects Precision as CRO for eRapa Phase 3 study in Europe - Investing.com

Mar 06, 2025
pulisher
Feb 12, 2025

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status - Barchart

Feb 12, 2025
pulisher
Feb 11, 2025

Biodexa Pharmaceuticals Plc ADR [BDRX] Is Currently 31.94 above its 200 Period Moving Avg: What Does This Mean? - The DBT News

Feb 11, 2025
pulisher
Feb 10, 2025

why Teva- Pharmaceutical Industries Ltd. ADR [TEVA] is a Good Choice for Investors After New Price Target of $24.71 - The DBT News

Feb 10, 2025
pulisher
Feb 10, 2025

Palantir Technologies Inc [PLTR] Is Currently -0.39 below its 200 Period Moving Avg: What Does This Mean? - The DBT News

Feb 10, 2025
pulisher
Feb 10, 2025

Biodexa Pharmaceuticals Plc ADR (BDRX) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle

Feb 10, 2025
pulisher
Feb 10, 2025

Hesai Group ADR (HSAI) Shares Up Despite Recent Market Volatility - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

Biodexa Pharmaceuticals Plc ADR (BDRX) vs. Its Peers: A Comparison - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

Omega Therapeutics Inc (OMGA) Stock: A SWOT Analysis - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis - GlobeNewswire

Feb 10, 2025
pulisher
Feb 10, 2025

AES Corp (AES) Shares Down Despite Recent Market Volatility - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

Altus Power Inc (AMPS) vs. Its Peers: A Comparison - The News Heater

Feb 10, 2025
pulisher
Jan 30, 2025

Skechers (SKX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Jan 30, 2025
pulisher
Jan 30, 2025

Is Argenx (ARGX) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Jan 30, 2025
pulisher
Jan 14, 2025

Are Medical Stocks Lagging Argenx (ARGX) This Year? - Yahoo Finance

Jan 14, 2025
pulisher
Nov 22, 2024

Result of General Meeting - GlobeNewswire

Nov 22, 2024
pulisher
Nov 12, 2024

Biodexa Pharmaceuticals regains Nasdaq compliance - Investing.com

Nov 12, 2024
$77.55
price up icon 0.23%
$37.12
price down icon 0.40%
$105.18
price up icon 0.17%
$26.66
price down icon 0.30%
$110.05
price down icon 1.28%
biotechnology ONC
$299.94
price down icon 1.90%
Kapitalisierung:     |  Volumen (24h):